Incircular BV was founded by three (bio)chemists at VU Amsterdam who have developed a novel technology for stabilizing proteins: INCYPRO. In their recently launched spin-off, Saskia Neubacher, Sven Hennig and Tom Grossmann will use this technology to stabilize proteins for applications in drug development, diagnostic testing, and biocatalysis.
Proteins are a class of large, natural molecules produced in all organisms. They include enzymes, antibodies, hormones and many more, and are involved in all cellular processes. The 3D structure of proteins is essential for their specific function and performance but many proteins lose their function outside of the natural environment because their 3D structure is fragile. This led the VU Amsterdam scientists to develop the INCYPRO protein stabilization technology. INCYPRO supports the natural 3D structure of proteins through a design process that enables the precise chemical modification of a protein and thus allows novel applications.
The development of novel drugs
Most drugs on the market today target disease-associated proteins. To enable an efficient drug development process for currently untreatable diseases, such as Alzheimer’s disease and cancer, it is important to isolate the disease-associated proteins for in-depth analysis and screening. INCYPRO-stabilized proteins can thus be very useful for the development of safe and efficient novel drugs. Incircular will use the INCYPRO technology to deliver solutions for its clients, which include companies in the pharmaceutical sector whose applications are adversely impacted by the instability of their proteins. The company provides these clients with robust proteins that they need to facilitate their application. Neubacher: “The INCYPRO technology has the potential to enable the discovery of future drugs. It would be truly amazing if our work could improve the quality of life of many patients.”
The scientists from the Department of Chemistry & Pharmaceutical Sciences and the Amsterdam Institute of Molecular & Life Sciences launched their new company under the guidance of Innovation Exchange Amsterdam (IXA) and the Demonstrator Lab. In addition, the team of scientists has received funding from the Dutch Research Council (NWO) and the European Research Council (ERC). In 2019, the INCYPRO technology reached the finals of the competition for the Amsterdam Science & Innovation Award.
Recently, Google for Startups announced that startup Lalaland.ai – co-founded by VU Amsterdam alumni International Business Administration Michael Musandu and Ugnius Rimsa – was one of the 30 selected for Google’s Black Founder Fund. Lalaland generates and hyper personalizes fully human body models using Artificial Intelligence. In October 2020, the Google for Startups Black Founders Fund announced a $2 million initiative […]News
Doorstart voor veertigplussers, na ‘corona’ Gezond ouder worden willen we allemaal. Hoe we dat doen, verschilt van persoon tot persoon. Wat voor de één werkt, werkt voor de ander niet. Voor veel mensen is het echter niet eenvoudig om te bedenken met welke leefstijl zij het beste gezond ouder worden. De Amsterdamse start-up Fitsurance ontwikkelde […]News
GymStory – co-founded by VU Amsterdam alumnus Business Administration Lars van der Wal – has been named by MT/Sprout in the top 5 startups working hard from the Netherlands to conquer the sports world! GymStory (resident of Amsterdam Venture Studios on VU Campus) makes it easy to keep track of fitness activities and share them with others: a kind of […]News